Medical instrument and method of use

Information

  • Patent Grant
  • 9204889
  • Patent Number
    9,204,889
  • Date Filed
    Monday, September 12, 2011
    12 years ago
  • Date Issued
    Tuesday, December 8, 2015
    8 years ago
Abstract
This invention relates to surgical instruments for applying energy to tissue using a vapor-to-liquid phase transition which delivers large amount of energy to the targeted tissue. In one embodiment, the system is configured for volumetric removal of tissue by means of high velocity ejection of a vapor media from a first vapor port proximate to soft tissue wherein the vapor-to-liquid phase change of the media applies energy to the tissue. The system provides a second port coupled to a suction source that cooperates with the first vapor port to suction tissue debris from the targeted site.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


This invention relates to surgical instruments for applying energy to tissue, and more particularly relates to a system for volumetric removal of tissue by means of high velocity ejection of a vapor media from a first vapor port proximate to soft tissue wherein the vapor-to-liquid phase change of the media applies energy to the tissue. Contemporaneously, the system provides a second port coupled to a suction source that cooperates with the first vapor port to suction tissue debris from the targeted site.


2. Description of the Related Art


Various types of radiofrequency (RI) and laser surgical instruments have been developed for delivering thermal energy to tissue, for example to ablate tissue, to cause hemostasis, to weld tissue or to cause a thermoplastic remodeling of tissue. While such prior art forms of energy delivery are suitable for some applications, Rf and laser energy typically cannot cause highly “controlled” and “localized” thermal effects that are desirable in microsurgeries or other precision surgeries. In general, the non-linear or non-uniform characteristics of tissue affect both laser and Rf energy distributions in tissue.


What is needed for many surgical procedures is an instrument and technique that can controllably deliver energy to tissue for volumetric tissue removal or tissue cutting without the possibility of desiccation or charring of adjacent tissues, and without collateral thermal damage.


SUMMARY OF THE INVENTION

The present invention is adapted to provide improved methods of controlled energy delivery to localized tissue volumes, for example for volumetric tissue removal or thermoplastic remodeling of tissue.


In general, the thermally-mediated treatment method comprises causing a vapor-to-liquid phase state change in a selected media at a targeted tissue site thereby applying thermal energy substantially equal to the heat of vaporization of the selected media to said tissue site. The thermally-mediated therapy can be delivered to tissue by such vapor-to-liquid phase transitions, or “internal energy” releases, about the working surfaces of several types of instruments for endoluminal treatments or for soft tissue thermotherapies. FIGS. 1A and 1B illustrate the phenomena of phase transitional releases of internal energies. Such internal energy involves energy on the molecular and atomic scale—and in polyatomic gases is directly related to intermolecular attractive forces, as well as rotational and vibrational kinetic energy. In other words, the method of the invention exploits the phenomenon of internal energy transitions between gaseous and liquid phases that involve very large amounts of energy compared to specific heat.


It has been found that the controlled application of internal energies in an introduced media-tissue interaction solves many of the vexing problems associated with energy-tissue interactions in Rf, laser and ultrasound modalities. The apparatus of the invention provides a fluid-carrying chamber in the interior of the device or working end. A source provides liquid media to the interior chamber wherein energy is applied to instantly vaporize the media. In the process of the liquid-to-vapor phase transition of a saline media in the interior of the working end, large amounts of energy are added to overcome the cohesive forces between molecules in the liquid, and an additional amount of energy is requires to expand the liquid 1000+ percent (PAD) into a resulting vapor phase (see FIG. 1A). Conversely, in the vapor-to-liquid transition, such energy will be released at the phase transitions at the targeted tissue interface. That is, the heat of vaporization is released in tissue when the media transitioning from gaseous phase to liquid phase wherein the random, disordered motion of molecules in the vapor regain cohesion to convert to a liquid media. This release of energy (defined as the capacity for doing work) relating to intermolecular attractive forces is transformed into therapeutic heat for a thermotherapy within a targeted body structure. Heat flow and work are both ways of transferring energy.


In FIG. 1A, the simplified visualization of internal energy is useful for understanding phase transition phenomena that involve internal energy transitions between liquid and vapor phases. If heat were added at a constant rate in FIG. 1A (graphically represented as 5 calories/gm blocks) to elevate the temperature of water through its phase change to a vapor phase, the additional energy required to achieve the phase change (latent heat of vaporization) is represented by the large number of 110+ blocks of energy at 100° C. in FIG. 1A. Still referring to FIG. 1A, it can be easily understood that all other prior art ablation modalities—Rf, laser, microwave and ultrasound—create energy densities by simply ramping up calories/gm as indicated by the temperature range from 37° C. through 100° C. as in FIG. 1A. The prior art modalities make no use of the phenomenon of phase transition energies as depicted in FIG. 1A.



FIG. 1B graphically represents a block diagram relating to energy delivery aspects of the present invention. The system provides for insulative containment of an initial primary energy-media within an interior chamber of an instrument's working end. The initial, ascendant energy-media interaction delivers energy sufficient to achieve the heat of vaporization of a selected liquid media such as saline within an interior of the instrument body. This aspect of the technology requires an inventive energy source and controller—since energy application from the source to the selected media (Rf, laser, microwave etc.) must be modulated between very large energy densities to initially surpass the latent heat of vaporization of the media within milliseconds, and possible subsequent lesser energy densities for maintaining the media in its vapor phase. Additionally, the energy delivery system is coupled to a pressure control system for replenishing the selected liquid phase media at the required rate—and optionally for controlling propagation velocity of the vapor phase media from the working end surface of the instrument. In use, the method of the invention comprises the controlled deposition of a large amount of energy—the heat of vaporization as in FIG. 1A—when the vapor-to-liquid phase transition is controlled at the vapor media-tissue interface. The vapor-to-liquid phase transition deposits about 580 cal/gram within the targeted tissue site to perform the thermal ablation.


In one embodiment, the system is configured for ablation and extraction of soft tissue, for example in treating a disc. The flow of vapor is controlled by a computer controller to cause a selected pressure, a selected volume of vapor to be ejected from a working end port. Contemporaneous with tissue contact, the vapor undergoes a vapor-to-liquid phase transition which delivers large amount of energy to the targeted tissue to obliterate or ablate the tissue. In one embodiment, the system causes volumetric removal of tissue by high velocity ejection of the vapor media from a first vapor port. The system provides a second port coupled to a suction source that cooperates with the first vapor port to suction tissue debris from the targeted site.


Additional advantages of the invention will be apparent from the following description, the accompanying drawings and the appended claims.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A is a graphical depiction of the quantity of energy needed to achieve the heat of vaporization of water.



FIG. 1B is a diagram of phase change energy release that underlies one method of the invention.



FIG. 2A is a perspective view of the working end of an exemplary Type “A” probe of the present invention with an openable-closeable tissue engaging structure in a first open position.



FIG. 2B is a perspective view similar to FIG. 2A probe of the present invention in a second closed position.



FIG. 3 is a cut-away view of the working end of FIGS. 2A-2B.



FIG. 4 is a perspective view of the working end of FIG. 3 capturing an exemplary tissue volume.



FIGS. 5-6 are sectional schematic views of working end of FIG. 3 depicting, in sequence, the steps of a method of the present invention to seal or weld a targeted tissue volume, FIG. 5 illustrating the pressurized delivery of a liquid media to an interior channel, and FIG. 6 depicting an electrical discharge that causes a liquid-to-gas phase change as well as the ejection of the vapor media into the targeted tissue to thermally seal engaged tissue.



FIG. 7 a cut-away of a Type “B” system with a thermal energy delivery mechanism for a liquid-to-vapor conversion of a pressurized inflow of a saline solution in a probe handle that is coupled to an elongated introducer with a working end configured for delivery of vapor to soft tissue, such as a disc nucleus.



FIG. 8 is view of a working end of the probe of FIG. 7.



FIG. 9A is a view of a method of using the probe working end of FIG. 8 to volumetrically remove disc nucleus tissue.



FIG. 9B is a view of an alternative working end similar to FIG. 8.



FIG. 9C is a view of another alternative working end similar to FIGS. 8 and 9B.



FIG. 9D is a view of another alternative working end similar to that of FIG. 9C with a cutting loop for cutting soft tissue.



FIG. 10 is another embodiment similar to that of FIG. 7 with an alternative system for delivering vapor to soft tissue together with introducing a second media to control the mass average temperature of the vapor.



FIG. 11 is another embodiment similar to that of FIG. 7 with an alternative system for delivering thermal energy.





DETAILED DESCRIPTION OF THE INVENTION

1. Type “A” Thermotherapy Instrument. Referring to FIGS. 2A, 2B and 3, the working end 10 of a Type “A” system 5 of the present invention is shown that is adapted for endoscopic procedures in which a tissue volume T targeted for treatment (a thermoplasty) can be captured by a loop structure. The working end 10 comprises a body 11 of insulator material (see FIG. 3) coupled to the distal end of introducer member 12 extending along axis 15. In this exemplary embodiment, the working end 10 has a generally cylindrical cross-section and is made of any suitable material such as plastic, ceramic, glass, metal or a combination thereof. The working end 10 is substantially small in diameter (e.g., 2 mm to 5 mm) and in this embodiment is coupled to an elongate flexible introducer member 12 to cooperate with a working channel in an endoscope. Alternatively, the working end 10 may be coupled to a rigid shaft member having a suitable 1 mm to 5 mm or larger diameter to cooperate with a trocar sleeve for use in endoscopic or microsurgical procedures. A proximal handle portion 14 of the instrument indicated by the block diagram of FIG. 2A carries the various actuator mechanisms known in the art for actuating components of the instrument.


In FIGS. 2A, 2B and 3, it can be seen that the working end 10 carries an openable and closeable structure for capturing tissue between a first tissue-engaging surface 20A and a second tissue-engaging surface 20B. In this exemplary embodiment, the working end 10 and first tissue-engaging surface 20A comprises a non-moving component indicated at 22A that is defined by the exposed distal end of body 11 of working end 10. The second tissue-engaging surface 20B is carried in a moving component that comprises a flexible loop structure indicated at 22B.


The second moving component or flexible loop 22B is actuatable by a slidable portion 24a of the loop that extends through a slot 25 in the working end to an actuator in the handle portion 14 as is known in the art (see FIG. 3). The other end 24b of the loop structure 22B is fixed in body 11. While such an in-line (or axial) flexible slidable member is preferred as the tissue-capturing mechanism for a small diameter flexible catheter-type instrument, it should be appreciated that any openable and closable jaw structure known in the art falls within the scope of the invention, including forms of paired jaws with cam-surface actuation or conventional pin-type hinges and actuator mechanisms: FIG. 2A illustrates the first and second tissue-engaging surfaces 20A and 20B in a first spaced apart or open position. FIG. 2B shows the first and second surfaces 20A and 20B moved toward a second closed position.


Now turning to the fluid-to-gas energy delivery means of the invention, referring to FIG. 3, it can be seen that the insulated or non-conductive body 11 of working end 10 carries an interior chamber indicated at 30 communicating with lumen 33 that are together adapted for delivery and transient confinement of a fluid media M that flows into chamber 30. The chamber 30 communicates via lumen 33 with a fluid media source 35 that may be remote from the device, or a fluid reservoir (coupled to a remote pressure source) carried within introducer 12 or carried within a handle portion 14. The term fluid or flowable media source 35 is defined to include a positive pressure inflow system which preferably is any suitable high pressure pump means known in the art. The fluid delivery lumen 33 transitions to chamber 30 at proximal end portion 34a thereof. The distal end portion 34b of chamber 30 has a reduced cross-section that functions to direct vapor media through a small outlet or nozzle indicated at 38.


Of particular interest, still referring to FIG. 3, paired spaced apart electrode elements 40A and 40B are exposed in surface 42 of interior fluid confinement chamber 30. In this exemplary embodiment, the electrode elements 40A and 40B comprise circumferential exposed surfaces of a conductive material positioned at opposing proximal and distal ends of interior chamber 30, but other arrangements are possible. The invention can utilize any suitable configuration of spaced apart electrodes (e.g., such as concentric electrode surfaces, intertwined helical electrode surfaces, adjustable spaced apart surfaces, or porous electrodes) about at least one confinement chamber 30 or lumen portion of the system. Alternatively, each electrode can comprise one or more projecting elements that project into the chamber. The exemplary embodiment of FIG. 3 shows an elongate chamber having an axial dimension indicated at A and diameter or cross-section indicated at B. The axial dimension may range from about 0.1 mm to 20.0 mm and may be singular or plural as described below. The diameter B may range from micron dimensions (e.g., 0.5 μm) for miniaturized instruments to a larger dimension (e.g., 5.0 mm) for larger instruments for causing the thermally induced liquid-to-vapor transformation required to enable the novel phase change energy-tissue interaction of the invention. The electrodes are of any suitable material such as stainless steel, aluminum, nickel titanium, platinum, gold, or copper. Each electrode surface preferably has a toothed surface texture indicated at 43 that includes hatching, projecting elements or surface asperities for better delivering high energy densities in the fluid proximate to the electrode. The electrical current to the working end 10 may be switched on and off by a foot pedal or any other suitable means such as a switch in handle 14.



FIG. 3 further shows that a preferred shape is formed into the tissue-engaging surface 20A to better perform the method of fusing tissue. As can be seen in FIGS. 2B and 3, the first tissue-engaging surface 20A is generally concave so as to be adapted to receive a greater tissue volume in the central portion of surface 20A. The second tissue-engaging surface 20B is flexible and naturally will be concave in the distal or opposite direction when tissue is engaged between surfaces 20A and 20B. This preferred shape structure allows for controllable compression of the thick targeted tissue volumes T centrally exposed to the energy delivery means and helps prevent conductance of thermal effects to collateral tissue regions CT (see FIG. 4) and as will be described in greater detail below.



FIGS. 2A and 3 show that first tissue-engaging surface 20A defines an open structure of at least one aperture or passageway indicated at 45 that allows vapor to pass therethrough. The apertures 45 may have any cross-sectional shape and linear or angular route through surface 20A with a sectional dimension C in this embodiment ranging upwards from micron dimensions (e.g., 0.5 μm) to about 2.0 mm in a large surface 20A. The exemplary embodiment of FIG. 3 has an expanding cross-section transition chamber 47 proximate to the aperture grid that transitions between the distal end 34b of chamber 30 and the apertures 45. However, it should be appreciated that such a transition chamber 47 is optional and the terminal portion of chamber 30 may directly exit into a plurality of passageways that each communicate with an aperture 45 in the grid of the first engaging surface 20A. In a preferred embodiment, the second tissue-engaging surface 20B defines (optionally) a grid of apertures indicated at 50 that pass through the loop 22B. These apertures 50 may be any suitable dimension (cf. apertures 45) and are adapted to generally oppose the first tissue-engaging surface 20A when the surfaces 20A and 20B are in the second closed position, as shown in FIG. 2B.


The electrodes 40A and 40B of working end 10 have opposing polarities and are coupled to Rf generator or electrical source 55. FIG. 3 shows current-carrying wire leads 58a and 58b that are coupled to electrodes 40A and 40B and extend to electrical source 55 and controller 60. In a preferred embodiment of the invention, either tissue-engaging surface optionally includes a sensor 62 (or sensor array) that is in contact with the targeted tissue surface (see FIG. 2A). Such a sensor, for example a thermocouple known in the art, can measure temperature at the surface of the captured tissue. The sensor is coupled to controller 60 by a lead (not shown) and can be used to modulate or terminate power delivery as will be described next in the method of the invention.


Operation and use of the working end of FIGS. 2A, 2B and 3 in performing a method of treating tissue can be briefly described as follows, for example in an endoscopic polyp removal procedure. As can be understood from FIG. 4, the working end 10 is carried by an elongate catheter-type member 12 that is introduced through a working channel 70 of an endoscope 72 to a working space. In this case, the tissue T targeted for sealing is a medial portion 78 of a polyp 80 in a colon 82. It can be easily understood that the slidable movement of the loop member 22B can capture the polyp 80 in the device as shown in FIG. 4 after being lassoed. The objective of the tissue treatment is to seal the medial portion of the polyp with the inventive thermotherapy. Thereafter, utilize a separate cutting instrument is used to cut through the sealed portion, and the excised polyp is retrieved for biopsy purposes.


Now turning to FIGS. 5 and 6, two sequential schematic views of the working end engaging tissue T are provided to illustrate the energy-tissue interaction caused by the method of the invention. FIG. 5 depicts an initial step of the method wherein the operator sends a signal to the controller 60 to delivery fluid media M (e.g., saline solution or sterile water) through lumen 33 into chamber 30. FIG. 6 depicts the next step of the method wherein the controller delivers an intense discharge of electrical energy to the paired electrode elements 40A and 40B within chamber 30 indicated by electric arc or electric field EF. The electrical discharge provides energy exceeding the heat of vaporization of the contained fluid volume. The explosive vaporization of fluid media M (of FIG. 5) into a vapor or gas media is indicated at M′ in FIG. 6. The greatly increased volume of gas media M′ results in the gas being ejected from chamber 30 at high velocity through apertures 45 of surface 20A into the targeted tissue T. The liquid-to-vapor transition caused by the electrical discharge results in the vapor media M′ having a temperature of 100° C. or more as well as carrying the heat of vaporization to deliver thermal effects into or through the targeted tissue T, as indicated graphically by the shaded regions of gas flow in FIG. 6. The fluid source and its pressure mechanism can provide any desired level of vapor ejection pressure. Depending on the character of the introduced liquid media, the media is altered from a first lesser temperature to a second greater temperature in the range of 100° C. or higher depending on pressure. The ejection of vapor media M′ and its condensation will uniformly and very rapidly elevate the temperature of the engaged tissue to the desired range of about 65° C. to 100° C. to cause hydrothermal denaturation of proteins in the tissue, and to cause optimal fluid inter-mixing of tissue constituents that will result in an effective seal. In effect, the vapor-to-liquid phase transition of the ejected media M′ will deposit heat equal to the heat of vaporization (also sometimes called the heat of condensation) in the tissue. At the same time, as the heat of vaporization of media M′ is absorbed by water in the targeted tissue, the media converts back to a liquid thus hydrating the targeted tissue T. Such protein denaturation by hydrothermal effects differentiates this method of tissue sealing or fusion from all other forms of energy delivery, such as radiofrequency energy delivery. All other forms of energy delivery vaporize intra- and extracellular fluids and cause tissue desiccation, dehydration or charring which is undesirable for the intermixing of denatured tissue constituents into a proteinaceous amalgam.


The above electrical energy deliver step is continuous or can be repeated at a high repetition rate to cause a pulsed form of thermal energy delivery in the engaged tissue. The fluid media M inflow may be continuous or pulsed to substantially fill chamber 30 before an electrical discharge is caused therein. The repetition rate of electrical discharges may be from about 1 Hz to 1000 Hz. More preferably, the repetition rate is from about 10 Hz to 200 Hz. The selected repetition rate preferably provides an interval between electrical discharges that allows for thermal relaxation of tissue, that may range from about 10 ms to 500 ms. The electrical source or voltage source 55 may provide a voltage ranging between about 20 volts and 10,000 volts to cause instant vaporization of the volume of fluid media M captured between the electrode elements 40A and 40B. After a selected time interval of such energy application to tissue T, that may range from about 1 second to 30 seconds, and preferably from about 5 to 20 seconds, the engaged tissue will be contain a core region in which the tissue constituents are denatured and intermixed under relatively high compression between surfaces 20A and 20B. Upon disengagement and cooling of the targeted tissue T, the treated tissue will be fused or welded. Over time, the body's wound healing response will reconstitute the treated tissue by means of fibrosis to create a collagenous volume or scar-like tissue.


2. Type “B” Thermotherapy Instrument. Now referring to FIGS. 7 and 8, another embodiment of vapor generation and delivery system 200 is shown. In the previous embodiment, the working end was optimized for engaging and sealing tissue with a working surface that is in contact with tissue. In the embodiment of FIGS. 7 and 8, the working end ejects vapor from port 202 for the controlled application of energy by means of a vapor-to liquid phase change energy release for soft tissue removal, for example, to remove disc nucleus tissue. The system can also be used for removal of other soft tissue such as adipose tissue, tumors and the like. In one embodiment, the vapor quality is adapted for collapse (condensation) as well the high velocity vapor (and vapor droplets) applying mechanical force to the soft tissue to assist in the tissue obliteration. The system and introducer sleeve 205 as shown in FIGS. 7 and 8 also includes a negative pressure source coupled to an outflow lumen or channel for extracting condensed vapor and tissue debris from the targeted site, as will be described in more detail below.


In FIG. 7, it can be seen that system 200 includes a handle portion 204 that transitions into an introducer sleeve 205 that has an elongated dimension for introduction into a patient's body percutaneously, or through a body cavity or a body lumen. The diameter of introducer sleeve 205 can range from about 1 mm to 6 mm or more. In one embodiment, the introducer sleeve is configured for introduction percutaneously into patient's disc as indicated in FIG. 9.


In one embodiment, the introducer sleeve 205 is fabricated of a temperature resistant polymer or a metal in combination with a polymeric coating. The introducer sleeve 205 can be rigid, deformable or articulatable as in known in the art. In one embodiment, the introducer sleeve 205 is a metal coated with a polymer having a low thermal conductivity, for example less than about 1.0 W/m-K, and preferably less than about 0.50 W/m-K. In one example, an unreinforced polyetheretherketone (PEEK) has a thermal conductivity of about 0.25 W/m-K and can be used for inner and/or outer layers of the introducer. Alternatively, the introducer sleeve 205 can be of PEEK. PEEK is high temperature resistant engineered thermoplastic with excellent chemical and fatigue resistance plus thermal stability. PEEK had a maximum continuous working temperature of 480° F. and retains its mechanical properties up to 570° F. in high-pressure environments. Other materials used in the introducer can comprise formulations or blends of polymers that include, but are not limited to PTFE, polyethylene terephthalate (PET), or PEBAX. PTFE (polytetrafluoroethylene) is a fluoropolymer which has high thermal stability (up to 260° C.), is chemically inert, has a very low dielectric constant, a very low surface friction and is inherently flame retardant. A range of homo and co-fluoropolymers are commercialized under such names as Teflon®, Tefzel®, Neoflon®, Polyflon® and Hyflon®. In another embodiment, the introducer sleeve can carry another layer of a suitable thickness that comprises a low thermal conductivity region such as an air gaps, a layer of an insulative ceramic or glass microspheres or fibers, or at least one lumen that carries a cryofluid in communication with a cryogenic fluid source as in known in the art.


Now turning to FIG. 7, the cut-away view of handle 204 shows that an interior chamber 225 is formed within the interior of an insulator material indicated at 228 such as a ceramic or a combination of materials to insulate the interior chamber 225 from the surface of the handle. An inflow channel 230 communicates with pressurized inflow source 240 of fluid or liquid media via flexible tube 242 coupled to fitting 244. A computer controller 245 is provided to control parameters of fluid inflows to the interior chamber 225. The interior chamber 225 has a distal region in which media flows transition to outflow channel 212 that extends to the working end 215. In FIG. 8, it can be seen that Rf source 250 (also operatively connected to controller 245) has first polarity (+) lead 252a and opposing second polarity (−) lead 252b that are coupled respectively to first and second conductive surfaces or electrodes 255A and 255B exposed in interior chamber 225 that serve as a thermal energy delivery mechanism. The first conductive surface 255A is the outer surface of elongated sleeve 256 with bore 258 therein having diffuser ports 260 in the sleeve wall for introducing pressurized liquid media M into the interior chamber 225. The diffuser ports 260 have a suitable dimension and configuration for diffusing or atomizing a high pressure inflow of flow media M from source 240, which preferably is a saline solution. The second polarity (−) lead is coupled to conductive surface 255B which comprises a radially outward surface of interior chamber 225. In the embodiment shown in FIG. 7, it can be seen that the first and second conductive surfaces 255A and 255B are concentric, extend over a substantial length of the handle and have a large surface area with a fixed spaced apart radial dimension indicated at 262. The radial dimension 262 between the electrode surfaces is selected to match the particular impedance and other operating characteristics of the Rf generator.


The system also includes a negative pressure source 270 that communicates with an outflow channel 276 and outflow lumen 278 in the introducer sleeve, as can be seen in the cut-away view of FIG. 7. In FIG. 8, it can be seen that the working end 215 has a suction port 280 that is configured for the aspiration of tissue debris from the targeted site. The ablation, obliteration and volumetric removal of soft tissue is enabled by the phase change energy release of the vapor transitioning to a liquid as well as mechanical effect of vapor engaging the soft tissue. In the embodiment of FIG. 8, the vapor outlet (or a plurality of outlets) 202 (i) eject vapor along an axis 282 in a recess 284 that is at least in partly oriented toward an axis of the aspiration port 280, or (ii) that deflect vapor toward at least one aspiration port 280. In any embodiment, the inflow pressure of the media can range upward from about 5 psi. In this embodiment, the inflow pressure is elevate greatly to the range of about 5,000 psi to 50,000 psi with a very small media outlet in the range of 0.005″ to 0.025″ or other suitable dimension and pressure wherein water droplets can apply mechanical energy to scour, damage or obliterate soft tissue. In this embodiment, the system includes the Rf source 250 described above that are operatively coupled to the media inflow pressure source 240 and controller 245 that can apply energy to cause a selected level of vaporization. Optionally, the system can be configured to pulse the energy delivery or the vapor flows at 10 Hz to 500 Hz which it has been found is useful for soft tissue removal. In one method of use, the system can control pressure and flow volume for allowing the vapor flow to obliterate or scour soft disc nucleus tissue while not allowing obliteration of the disc annulus. The system thus allows for tissue-discrimination and ablation based on tissue characteristics such as tissue density, tissue fibrous level and the like. The working end 215 of FIG. 8 is thus well suited for volumetric removal of disc nucleus tissue. Such treatments are needed for new procedures that implant an artificial nucleus, for annulus repair treatments.


Referring to FIG. 7, in a method of operation, the system injects a volume of liquid saline flow media M at a selected rate under pressure from source 240 which is diffused and atomized by ports 260 as the media enters interior chamber 225. Contemporaneous with injection and diffusion of the volume of saline, the system delivers sufficient current from source 250 and controller 245 to the conductive atomized saline via the opposing polarity surfaces 255A and 250B which instantly vaporize the H2O in the flow media M to generate a vapor M′ that is injected from interior chamber 225 into lumen or channel 212 of introducer sleeve 205. The instantaneous increase in volume of media in the liquid-to-vapor phase transition greatly increases interior pressures in interior chamber 225 to thereby accelerate the flow into and through the introducer sleeve to working end 215. Contemporaneous with the ejection of vapor from the working end, the negative pressure source 270 is actuated to suction the collapsing vapor and tissue debris into port 280 and aspiration channel 278. In any embodiment, the vapor aspiration port or ports 280 are substantially larger in cross-section than the vapor outlet or outlets 202 to accommodate the increase in volume of the condensate as well as tissue debris.


Turning back to FIG. 7, the system and handle 204 can include an optional pressure relief valve schematically indicated at 264 so that any overpressures in the interior chamber are released. The release of any overpressure can be vented through an additional lumen in the supply tube 242 or to another chamber in the handle.



FIG. 9A further depicts a method of the invention in treating a patient's disc for removal of a disc nucleus. In FIG. 9A, it can be seen that the physician has navigated the working end 215 to the targeted nucleus region 285 of a disc 286 as in known in the art under imaging such as fluoroscopy. In one embodiment, the working end carries radiopaque marking to allow the physician to see the angular orientation of the working end. In a next step, the physician sets the pressure, volume of vapor and rate of vapor delivery in the fluid inflow controller 245 that is operatively coupled to the fluid source 240, Rf source 250 and negative pressure source 270. The controller 245 operates from pre-sets that select a power level and duration of Rf energy delivery to cooperate with the selected volume of inflowing media M. The controller 245 also operates using pre-sets for simultaneous actuation of the negative pressure source 270 that communicates with lumen 278 in introducer sleeve 205 for suction of tissue debris and vapor condensate. The physician then can move the working end 215 axially, rotationally and angularly to remove the disc nucleus while the preventing damage to the annulus.



FIGS. 9B and 9C illustrate working ends 215 that are similar to that of FIG. 8 with different arrangements of vapor outlets 220 and aspiration ports 280. In FIG. 9B, a recess 284 is at the distal end the introducer sleeve 205 with the vapor outlet 220 and aspiration port 280 generally opposing on another in the recess. In FIG. 9C, the introducer 205 includes a deflector portion indicated at 290 proximate the vapor outlet 202 for deflecting the flow of vapor toward the aspiration port. In the embodiment of FIG. 9C, the vapor inflow channel 212 and the aspiration channel 278 are in a concentric configuration. FIG. 9D illustrates a working end wherein the introducer sleeve 205 is rotatable at high speed together with a loop element 295 that can be deployed from the working end to cut or scour tissue contemporaneous with energy delivery as described above. The loop element can rotate at any speed from about 20 rpm to 10,000 rpm. In one embodiment, the loop 295 is made of a flexible, round cross-section polymer filament. In use, the filament will operate to cut soft tissue but flex to discriminate against cutting harder tissue. This system is useful in discriminating, for example, between the disc nucleus and the annulus. In another embodiment, the loop 295 is a metal with option blade edge that can be used, for example, to excise and extract soft tumor tissue in a breast, liver, lung or the like. The energy delivered by the vapor contemporaneously obliterates the tissue and can thermally seal the cavity created by the tissue extraction.


An optional pressure sensor 288 located at the distal end of the introducer 205 (FIG. 8) can be used to assist in determining pressures in the interior of the patient in a working region. MEMS-fabricated pressure sensors are known in the art and can be carried in the surface of the introducer or the balloon surface, for example, of the type fabricated by Integrated Sensing Systems, Inc., 391 Airport Industrial Drive, Ypsilanti, Mich. 48198. Such sensor can be linked back to controller 245 to adjust aspiration pressures or to terminate vapor flow. The MEMS sensor also can be an accelerometer linked to the controller for modulating or terminating vapor delivery in response to unwanted movement of the working end caused by the high pressure ejection of vapor.


In another embodiment and method of the invention, referring to FIG. 10, the system 300 can include a secondary pressurized media inflow source 305 that is adapted to introduce media or substance 310 (in the form of at least one of a gas, liquid or particulate) through channel 312 in the handle into channel 212 to combine with vapor media M′ after it is ejected from chamber 225. In a method of the invention, the system thus allows for controlling the average mass temperature of the vapor. In one embodiment, the additional media 310 comprises a bioinert gas or atomized fluid that is depressurized and introduced into the vapor for the purpose of reducing the mass average temperature of the injected media to lower than about 100° C. For example, the introduced media 310 can be depressurized CO2, N2, or O2 or atomized H2O. By this means, the mass average temperature can be less than 100° C., for example in the range of about 45° C. to 100° C. More preferably, the mass average temperature can be in the range of about 60° C. to 95° C. Still more preferably, the mass average temperature can be in the range of about 70° C. to 90° C.



FIG. 11 illustrates another system embodiment 400 with handle 402 that utilizes a resistive element 420 in interior chamber 425 to cause the liquid-to-vapor phase change in the inflowing media M. All other system components are similar to the previous embodiments and have similar reference numbers. The electrical leads 426a and 426b in this embodiment are coupled to opposing ends of resistive element 420. In one embodiment, the resistive element 420 comprises a flow permeable structure such as a syntactic material or open-cell material (FIG. 11). The terms “syntactic”, “open-cell” and “flow permeable” as used herein refer to any structure that has substantial porosity for allowing fluid flow therethrough. Such materials have the advantage of providing very high surface areas for conducting heat from an I2R heated material to pressurized media flows therein. The syntactic structure is further selected to provide an internal pore dimension that causes diffusion and atomization of high pressure inflows, for example of sterile water or saline. For example, the resistive element 420 can comprise a syntactic metal, resistive ceramic composite, or include a carbon portion. Such materials are available from ERG Materials and Aerospace Corp., 900 Stanford Avenue, Oakland, Calif. 94608 and Poco Graphite (http://www.poco.com). The open-cell material also can be an open cell foam that is metal plated, a sintered material, a plated entangled filament material, or any ordered or disordered structure commonly known in the art.


In the embodiment of FIG. 11, the system further includes a valve system 428 and recirculating channel 430 that are adapted for controlling the generation and release of vapor from working end 415. In the previous embodiments, the use of Rf energy delivery for vapor generation in chamber 225 (FIG. 7) can cause instantaneous high pressure flows of vapor. In the system embodiment of FIG. 11, the delivery of energy by means of resistive element 420 can require a fraction of a second or more to produce vapor from high pressure inflows of liquid media M. For this reason, the interior chamber 425 includes a recirculation channel 430 for a looped flow of vapor—or vapor and water droplets—that circulates back to inflow channel or the proximal end 432 of interior chamber 425. It should be appreciated that the recirculation channel 430 can be entirely housed in handle 402 or can circulate back to the source 245 or another intermediate chamber. The recirculation channel 430 also is operatively coupled to a pressure relief valve 262 as described above, and can further include a one-way valve indicated at 434. In operation of the embodiment, the system is actuated to create vapor which can circulate until a switch 435 coupled to controller 245 and valve 428 is actuated to release vapor M′ from interior chamber 425. In all other respects, the method of the invention is the same as described above.


The schematic view of system 400 in FIG. 11 depicts the valve 428 in the handle, but the valve can also be located in working end 415 or elsewhere in introducer sleeve 205. Such valve systems can be linked to controller 245 by electrical leads in the introducer wall. In another embodiment, the valve 428 can be in the working end 415 and the recirculation channel 430 also can extend through the introducer sleeve 205 to the working end 415. This system thus assures that high quality vapor will be ejected from the working end.


The scope of the invention includes the use valve system 428 and recirculating channel 430 in other embodiments that utilize Rf, laser microwave or other energy deliver mechanisms. For example, in an Rf energy system as in FIG. 7, the valve and recirculating channel 430 systems can be used to control slight inconsistencies in vapor generation due to varied liquid inflow rates that sometimes results in sputtering and incomplete vaporization or inflowing media.


In another embodiment similar to that of FIG. 11, the system can infuse heated water (or saline or another liquid) from an external source under high pressure into an enclosed interior chamber of the system. The system also includes a valve similar to valve 428 in FIG. 11. Upon opening of the valve, the release of pressurized fluid will in part release the energy that was exerted on the fluid in the form of pressure—which will be converted into the energy required to vaporize the heated fluid. This type of system has the advantage of not requiring a thermal energy source with sufficient capacity for vaporizing needed volumes of vapor. Instead, a pressurization mechanism combined with a less robust thermal energy delivery system can be used to produce the required volume of vapor. Such sources can be external to the handle of the introducer.


The scope of the invention included use of the system to apply energy from a phase-change release to tissue for tissue modification in various procedures. The system can be configured with a needle-like working end to treat tumor tissue in a prostate, liver, kidney, breast, lung, vertebra and the like. The system can be configured with a needle-like working end for ablating fibroids. In another embodiment, a very small gauge needle (e.g., 36 ga.) can be used with fiber optic viewing to treat macular degeneration for shrinking and sealing leaking microvasculature. As very small gauge needle also can be used in a vision correction treatment to treat the cornea. A series of spots around the cornea can be targeted with vapor to shrink collagen to create a steepened cornea for treating presbyopia or to treat hyperopia. In another embodiment, the system can use a phase change energy release in an endometrial ablation procedure. In another embodiment, the system can use a small gauge blunt-tipped vapor delivery device that used pulses of vapor to cut brain tissue without causing any collateral thermal damage. A similar device can be used in orthopedic surgery to cut ligaments, cartilage and the like. The system can use in a cutting loop for TURP procedures. The system also can be used for delivering energy to a body lumen such as a blood vessel. In another embodiment, the system can be used to shrink lung tissue to cause lung volume reduction.


Although particular embodiments of the present invention have been described above in detail, it will be understood that this description is merely for purposes of illustration and the above description of the invention is not exhaustive. Specific features of the invention are shown in some drawings and not in others, and this is for convenience only and any feature may be combined with another in accordance with the invention. A number of variations and alternatives will be apparent to one having ordinary skills in the art. Such alternatives and variations are intended to be included within the scope of the claims. Particular features that are presented in dependent claims can be combined and fall within the scope of the invention. The invention also encompasses embodiments as if dependent claims were alternatively written in a multiple dependent claim format with reference to other independent claims.

Claims
  • 1. A method of applying energy to soft tissue comprising: generating a flow of vapor within a chamber;recirculating the flow of vapor within the chamber to increase a vapor quality of the flow of vapor; andintroducing the flow of vapor into a targeted soft tissue at a high velocity wherein the vapor delivers thermal energy sufficient to modify the tissue and where the high velocity of the vapor applies mechanical energy sufficient to modify the tissue.
  • 2. The method of claim 1 wherein the introducing the flow of vapor includes the vapor undergoing a vapor-to-liquid phase transition thereby delivering the thermal energy.
  • 3. The method of claim 1, further comprising controlling at least one of the pressure of the flow of vapor, the volume of the flow of vapor and the duration of the flow of vapor.
  • 4. The method of claim 1, further comprising controlling the temperature of the heat of vaporization of the vapor.
  • 5. The method of claim 1 further including reducing the mass average temperature of the vapor flow with the controlled introduction of a selected media into the vapor flow, the selected media consisting of at least one of a gas, a liquid or particulate matter.
  • 6. The method of claim 5 wherein the selected media includes at least one of depressurized CO2, N2, O2 or H2O.
  • 7. A method as in claim 1 further comprising applying aspiration forces about the interface of the flow of vapor with the soft tissue for controlling the depth of tissue modification.
  • 8. A method as in claim 1 wherein introducing the flow of vapor includes deflecting the flow about an instrument working end for controlling the depth of tissue modification.
  • 9. A method as in claim 1 wherein introducing the flow of vapor includes allowing expansion of the vapor media in a recess in an instrument working end.
  • 10. The method of claim 1 wherein modifying tissue includes at least one of tissue ablation, obliteration and scouring.
  • 11. The method of claim 1 wherein modifying tissue includes controlling the parameters of the flow of vapor to obliterate a selected softer tissue while preventing obliteration of a selected harder tissue.
  • 12. The method of claim 1 wherein the tissue includes at least one of disc tissue, adipose tissue and tumorous tissue.
  • 13. The method of claim 1 further comprising generating the flow of vapor by at least one of resistive heating means, radiofrequency (Rf) energy means, microwave energy means, photonic energy means, magnetic induction energy means, compression and decompression means, and ultrasonic energy means.
  • 14. A method of applying energy to mammalian tissue comprising: generating a flow of vapor within a chamber;recirculating the flow of vapor within the chamber to increase a vapor quality of the flow of vapor; andintroducing the flow of vapor into a targeted tissue region at a high velocity wherein the vapor delivers thermal energy sufficient to modify the tissue and where the high velocity of the vapor applies mechanical energy sufficient to modify the tissue.
  • 15. The method of claim 14 wherein targeted tissue is in a patient's eye for treating macular degeneration.
  • 16. The method of claim 14 wherein targeted tissue is in a patient's cornea for shrinking collagen to alter corneal curvature.
  • 17. The method of claim 14 wherein targeted tissue is tumor tissue.
  • 18. The method of claim 14 wherein targeted tissue is a fibroid.
  • 19. The method of claim 14 wherein targeted tissue is endometrial tissue.
  • 20. The method of claim 14 wherein targeted tissue is a prostate.
  • 21. The method of claim 14 wherein targeted tissue is brain tissue.
  • 22. The method of claim 14 wherein targeted tissue is in a disc.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 11/244,329 filed Oct. 5, 2005, now U.S. Pat. No. 8,016,823, which claims the benefit of U.S. Provisional Patent Application No. 60/615,900 filed Oct. 5, 2004 and is a continuation-in-part of U.S. patent application Ser. No. 10/346,877 filed Jan. 18, 2003, now U.S. Pat. No. 6,911,028, which is a continuation-in-part of U.S. patent application Ser. No. 09/782,649 filed Feb. 12, 2001, now U.S. Pat. No. 6,508,816, which is a continuation-in-part of U.S. patent application Ser. No. 09/181,906 filed Oct. 28, 1998, now U.S. Pat. No. 6,210,404, which is a continuation-in-part of U.S. patent application Ser. No. 09/049,711 filed Mar. 27, 1998, now U.S. Pat. No. 6,053,909. U.S. patent application Ser. No. 11/244,329 is also a continuation-in-part of Ser. No. 10/681,625 filed Oct. 7, 2003, now U.S. Pat. No. 7,674,259, which claims the benefit of U.S. Provisional Patent Application No. 60/416,622 filed Oct. 7, 2002 and is a continuation-in-part of U.S. patent application Ser. No. 10/017,582 filed Dec. 7, 2001, now U.S. Pat. No. 6,669,694, which claims the benefit of U.S. Provisional Patent Application No. 60/254,487 filed Dec. 9, 2000. The contents of all the above applications are hereby incorporated by reference in their entirety.

US Referenced Citations (493)
Number Name Date Kind
408899 Bioch et al. Aug 1889 A
697181 Smith Apr 1902 A
1719750 Bridge et al. Sep 1927 A
3818913 Wallach Jun 1974 A
3880168 Berman Apr 1975 A
3930505 Wallach Jan 1976 A
4024866 Wallach May 1977 A
4083077 Knight et al. Apr 1978 A
4447227 Kotsanis May 1984 A
4672962 Hershenson Jun 1987 A
4682596 Bales et al. Jul 1987 A
4748979 Hershenson Jun 1988 A
4773410 Blackmer et al. Sep 1988 A
4793352 Eichenlaub Dec 1988 A
4872920 Flynn et al. Oct 1989 A
4898574 Uchiyama et al. Feb 1990 A
4915113 Holman Apr 1990 A
4950266 Sinofsky Aug 1990 A
4985027 Dressel Jan 1991 A
5006119 Acker et al. Apr 1991 A
5011566 Hoffman Apr 1991 A
5078736 Behl Jan 1992 A
5084043 Hertzmann et al. Jan 1992 A
5102410 Dressel Apr 1992 A
5112328 Taboada et al. May 1992 A
5122138 Manwaring Jun 1992 A
5158536 Sekins et al. Oct 1992 A
5162374 Mulieri et al. Nov 1992 A
5190539 Fletcher et al. Mar 1993 A
5217459 Kamerling Jun 1993 A
5217465 Steppe Jun 1993 A
5263951 Spears et al. Nov 1993 A
5277696 Hagen Jan 1994 A
5298298 Hoffman Mar 1994 A
5306274 Long Apr 1994 A
5318014 Carter Jun 1994 A
5331947 Shturman Jul 1994 A
5334190 Seiler Aug 1994 A
5344397 Heaven et al. Sep 1994 A
5348551 Spears et al. Sep 1994 A
5352512 Hoffman Oct 1994 A
5417686 Peterson et al. May 1995 A
5424620 Cheon et al. Jun 1995 A
5433708 Nichols et al. Jul 1995 A
5433739 Sluijter Jul 1995 A
5462521 Brucker et al. Oct 1995 A
5500012 Brucker et al. Mar 1996 A
5503638 Cooper et al. Apr 1996 A
5524620 Rosenschein Jun 1996 A
5529076 Schachar Jun 1996 A
5542928 Evans et al. Aug 1996 A
5549628 Cooper et al. Aug 1996 A
5554172 Horner et al. Sep 1996 A
5562608 Sekins et al. Oct 1996 A
5575803 Cooper et al. Nov 1996 A
5584872 LaFontaine et al. Dec 1996 A
5591157 Hennings et al. Jan 1997 A
5591162 Fletcher et al. Jan 1997 A
5616120 Andrew et al. Apr 1997 A
5620440 Heckele et al. Apr 1997 A
5669907 Platt, Jr. et al. Sep 1997 A
5681282 Eggers et al. Oct 1997 A
5683366 Eggers et al. Nov 1997 A
5695507 Auth et al. Dec 1997 A
5697281 Eggers et al. Dec 1997 A
5697536 Eggers et al. Dec 1997 A
5697882 Eggers et al. Dec 1997 A
5697909 Eggers et al. Dec 1997 A
5700262 Acosta et al. Dec 1997 A
5707352 Sekins et al. Jan 1998 A
5735811 Brisken Apr 1998 A
5741247 Rizoiu et al. Apr 1998 A
5741248 Stern et al. Apr 1998 A
5752965 Francis et al. May 1998 A
5755753 Knowlton May 1998 A
5782914 Schankereli Jul 1998 A
5785521 Rizoiu et al. Jul 1998 A
5800482 Pomeranz et al. Sep 1998 A
5810764 Eggers et al. Sep 1998 A
5824703 Clark, Jr. Oct 1998 A
5827268 Laufer Oct 1998 A
5836896 Rosenschein Nov 1998 A
5843019 Eggers et al. Dec 1998 A
5843073 Sinofsky Dec 1998 A
5871469 Eggers et al. Feb 1999 A
5879329 Ginsburg Mar 1999 A
5885243 Capetan et al. Mar 1999 A
5888198 Eggers et al. Mar 1999 A
5891095 Eggers et al. Apr 1999 A
5891134 Goble et al. Apr 1999 A
5913856 Chia et al. Jun 1999 A
5938660 Swartz et al. Aug 1999 A
5944686 Patterson et al. Aug 1999 A
5944715 Goble et al. Aug 1999 A
5957919 Laufer Sep 1999 A
5964752 Stone Oct 1999 A
5968037 Rizoiu Oct 1999 A
5980504 Sharkey et al. Nov 1999 A
5986662 Argiro et al. Nov 1999 A
5989212 Sussman et al. Nov 1999 A
5989238 Ginsburg Nov 1999 A
5989249 Kirwan Nov 1999 A
5989445 Wise et al. Nov 1999 A
5997499 Sussman et al. Dec 1999 A
6024095 Stanley, III Feb 2000 A
6024733 Eggers et al. Feb 2000 A
6027501 Goble et al. Feb 2000 A
6032077 Pomeranz Feb 2000 A
6032674 Eggers et al. Mar 2000 A
6047700 Eggers et al. Apr 2000 A
6053909 Shadduck Apr 2000 A
6056746 Goble et al. May 2000 A
6059011 Giolo May 2000 A
6063079 Hovda et al. May 2000 A
6063081 Mulier et al. May 2000 A
6066134 Eggers et al. May 2000 A
6066139 Ryan et al. May 2000 A
6074358 Andrew et al. Jun 2000 A
6080128 Sussman et al. Jun 2000 A
6080151 Swartz et al. Jun 2000 A
6083255 Laufer et al. Jul 2000 A
6095149 Sharkey et al. Aug 2000 A
6099251 LaFleur Aug 2000 A
6102046 Weinstein et al. Aug 2000 A
6102885 Bass Aug 2000 A
6106516 Bmassengill Aug 2000 A
6110162 Sussman et al. Aug 2000 A
6113722 Hoffman et al. Sep 2000 A
6126682 Sharkey et al. Oct 2000 A
6130671 Argiro Oct 2000 A
6139571 Fuller et al. Oct 2000 A
6149620 Baker et al. Nov 2000 A
6156036 Sussman et al. Dec 2000 A
6159194 Eggers et al. Dec 2000 A
6162232 Shadduck Dec 2000 A
6168594 LaFontaine et al. Jan 2001 B1
6174308 Goble et al. Jan 2001 B1
6179805 Sussman et al. Jan 2001 B1
6190381 Olsen et al. Feb 2001 B1
6194066 Hoffman Feb 2001 B1
6196989 Padget et al. Mar 2001 B1
6200333 Laufer Mar 2001 B1
6206848 Sussman et al. Mar 2001 B1
6210404 Shadduck Apr 2001 B1
6210405 Goble et al. Apr 2001 B1
6219059 Argiro Apr 2001 B1
6224592 Eggers et al. May 2001 B1
6231567 Rizoiu et al. May 2001 B1
6235020 Cheng et al. May 2001 B1
6238391 Olsen et al. May 2001 B1
6254597 Rizoiu et al. Jul 2001 B1
6261286 Goble et al. Jul 2001 B1
6261311 Sharkey et al. Jul 2001 B1
6264650 Hovda et al. Jul 2001 B1
6264651 Underwood et al. Jul 2001 B1
6264654 Swartz et al. Jul 2001 B1
6277112 Underwood et al. Aug 2001 B1
6283910 Bradshaw et al. Sep 2001 B1
6283961 Underwood et al. Sep 2001 B1
6283989 Laufer et al. Sep 2001 B1
6287274 Sussman et al. Sep 2001 B1
6290715 Sharkey et al. Sep 2001 B1
6296636 Cheng et al. Oct 2001 B1
6296638 Davidson et al. Oct 2001 B1
6299633 Laufer Oct 2001 B1
6300150 Venkatasubramanian Oct 2001 B1
6312408 Eggers et al. Nov 2001 B1
6312474 Francis et al. Nov 2001 B1
6315755 Sussman Nov 2001 B1
6319222 Andrew et al. Nov 2001 B1
6327505 Medhkour et al. Dec 2001 B1
6331171 Cohen Dec 2001 B1
6355032 Hovda et al. Mar 2002 B1
6375635 Moutafis et al. Apr 2002 B1
6379350 Sharkey et al. Apr 2002 B1
6391025 Weinstein et al. May 2002 B1
6394949 Crowley et al. May 2002 B1
6394996 Lawrence et al. May 2002 B1
6398759 Sussman et al. Jun 2002 B1
6398775 Perkins et al. Jun 2002 B1
6409723 Edwards Jun 2002 B1
6416508 Eggers et al. Jul 2002 B1
6458231 Wapner et al. Oct 2002 B1
6461350 Underwood et al. Oct 2002 B1
6464694 Massengil Oct 2002 B1
6464695 Hovda et al. Oct 2002 B2
6468270 Hovda et al. Oct 2002 B1
6468274 Alleyne et al. Oct 2002 B1
6468313 Claeson et al. Oct 2002 B1
6482201 Olsen et al. Nov 2002 B1
6482202 Goble et al. Nov 2002 B1
6488673 Laufer et al. Dec 2002 B1
6493589 Medhkour et al. Dec 2002 B1
6500173 Underwood et al. Dec 2002 B2
6508816 Shadduck Jan 2003 B2
6517568 Sharkey et al. Feb 2003 B1
6522930 Schaer et al. Feb 2003 B1
6527761 Soltesz et al. Mar 2003 B1
6527766 Bair Mar 2003 B1
6540741 Underwood et al. Apr 2003 B1
6544211 Andrew et al. Apr 2003 B1
6544248 Bass Apr 2003 B1
6547810 Sharkey et al. Apr 2003 B1
6558379 Batchelor et al. May 2003 B1
6575929 Sussman et al. Jun 2003 B2
6575968 Eggers et al. Jun 2003 B1
6579270 Sussman et al. Jun 2003 B2
6582423 Thapliyal et al. Jun 2003 B1
6585639 Kotmel et al. Jul 2003 B1
6588613 Pechenik et al. Jul 2003 B1
6589201 Sussman et al. Jul 2003 B1
6589204 Sussman et al. Jul 2003 B1
6592594 Rimbaugh et al. Jul 2003 B2
6595990 Weinstein et al. Jul 2003 B1
6599311 Biggs et al. Jul 2003 B1
6602248 Sharps et al. Aug 2003 B1
6605087 Swartz et al. Aug 2003 B2
6610043 Ingenito Aug 2003 B1
6620130 Ginsburg Sep 2003 B1
6620155 Underwood et al. Sep 2003 B2
6623444 Babaev Sep 2003 B2
6632193 Davison et al. Oct 2003 B1
6632220 Eggers et al. Oct 2003 B1
6634363 Danek et al. Oct 2003 B1
6648847 Sussman et al. Nov 2003 B2
6652594 Francis et al. Nov 2003 B2
6653525 Ingenito et al. Nov 2003 B2
6659106 Hovda et al. Dec 2003 B1
6669685 Rizoiu et al. Dec 2003 B1
6669694 Shadduck Dec 2003 B2
6676628 Sussman et al. Jan 2004 B2
6676629 Andrew et al. Jan 2004 B2
6679264 Deem et al. Jan 2004 B1
6679879 Shadduck Jan 2004 B2
6682520 Ingenito Jan 2004 B2
6682543 Barbut et al. Jan 2004 B2
6692494 Cooper et al. Feb 2004 B1
6695839 Sharkey et al. Feb 2004 B2
6699212 Kadziauskas et al. Mar 2004 B1
6699244 Carranza et al. Mar 2004 B2
6712811 Underwood et al. Mar 2004 B2
6712812 Roschak et al. Mar 2004 B2
6719738 Mehier Apr 2004 B2
6719754 Underwood et al. Apr 2004 B2
6723064 Babaev Apr 2004 B2
6726684 Woloszko et al. Apr 2004 B1
6726708 Lasheras Apr 2004 B2
6746447 Davison et al. Jun 2004 B2
6755794 Soukup Jun 2004 B2
6758846 Goble et al. Jul 2004 B2
6763836 Tasto et al. Jul 2004 B2
6764487 Mulier et al. Jul 2004 B2
6766202 Underwood et al. Jul 2004 B2
6770070 Balbierz Aug 2004 B1
6770071 Woloszko et al. Aug 2004 B2
6772012 Ricart et al. Aug 2004 B2
6776765 Soukup et al. Aug 2004 B2
6780180 Goble et al. Aug 2004 B1
6805130 Tasto et al. Oct 2004 B2
6813520 Truckai et al. Nov 2004 B2
6832996 Woloszko et al. Dec 2004 B2
6837884 Woloszko Jan 2005 B2
6837888 Ciarrocca et al. Jan 2005 B2
6852108 Barry et al. Feb 2005 B2
6860847 Alferness et al. Mar 2005 B2
6860868 Sussman et al. Mar 2005 B1
6875194 MacKool Apr 2005 B2
6896674 Woloszko et al. May 2005 B1
6896675 Leung et al. May 2005 B2
6901927 Deem et al. Jun 2005 B2
6904909 Andreas et al. Jun 2005 B2
6907881 Suki et al. Jun 2005 B2
6911028 Shadduck Jun 2005 B2
6918903 Bass Jul 2005 B2
6921385 Clements et al. Jul 2005 B2
6929640 Underwood et al. Aug 2005 B1
6949096 Davison et al. Sep 2005 B2
6955675 Jain Oct 2005 B2
6960182 Moutafis et al. Nov 2005 B2
6962584 Stone et al. Nov 2005 B1
6972014 Eum et al. Dec 2005 B2
6978174 Gelfand et al. Dec 2005 B2
6986769 Nelson et al. Jan 2006 B2
6991028 Comeaux et al. Jan 2006 B2
6991631 Woloszko et al. Jan 2006 B2
7022088 Keast et al. Apr 2006 B2
7031504 Argiro et al. Apr 2006 B1
7083612 Littrup et al. Aug 2006 B2
7094249 Broome et al. Aug 2006 B1
7128748 Mooradian et al. Oct 2006 B2
7136064 Zuiderveld Nov 2006 B2
7144402 Kuester, III Dec 2006 B2
7144588 Oray et al. Dec 2006 B2
7162303 Levin et al. Jan 2007 B2
7192400 Campbell et al. Mar 2007 B2
7233820 Gilboa Jun 2007 B2
7235070 Vanney Jun 2007 B2
7311708 McClurken Dec 2007 B2
7335195 Mehier Feb 2008 B2
7347859 Garabedian et al. Mar 2008 B2
7524315 Blott et al. Apr 2009 B2
7549987 Shadduck Jun 2009 B2
7585295 Ben-Nun Sep 2009 B2
7617005 Demarais et al. Nov 2009 B2
7620451 Demarais et al. Nov 2009 B2
7647115 Levin et al. Jan 2010 B2
7653438 Deem et al. Jan 2010 B2
7674259 Shadduck Mar 2010 B2
7717948 Demarais et al. May 2010 B2
7756583 Demarais et al. Jul 2010 B2
7815616 Boehringer et al. Oct 2010 B2
7815646 Hart Oct 2010 B2
7853333 Demarais Dec 2010 B2
7873417 Demarais et al. Jan 2011 B2
7892229 Shadduck et al. Feb 2011 B2
7937143 Demarais et al. May 2011 B2
7993323 Barry et al. Aug 2011 B2
8016823 Shadduck Sep 2011 B2
8131371 Demarals et al. Mar 2012 B2
8131372 Levin et al. Mar 2012 B2
8145316 Deem et al. Mar 2012 B2
8145317 Demarais et al. Mar 2012 B2
8150518 Levin et al. Apr 2012 B2
8150519 Demarais et al. Apr 2012 B2
8150520 Demarais et al. Apr 2012 B2
8175711 Demarais et al. May 2012 B2
8187269 Shadduck et al. May 2012 B2
8192424 Woloszko Jun 2012 B2
8313485 Shadduck Nov 2012 B2
8444636 Shadduck et al. May 2013 B2
8574226 Shadduck Nov 2013 B2
8579888 Hoey et al. Nov 2013 B2
8579892 Hoey et al. Nov 2013 B2
8579893 Hoey Nov 2013 B2
20010020167 Woloszko et al. Sep 2001 A1
20010029370 Hodva et al. Oct 2001 A1
20010037106 Shadduck Nov 2001 A1
20020049438 Sharkey et al. Apr 2002 A1
20020077516 Flanigan Jun 2002 A1
20020078956 Sharpe et al. Jun 2002 A1
20020082667 Shadduck Jun 2002 A1
20020095152 Ciarrocca et al. Jul 2002 A1
20020111386 Sekins et al. Aug 2002 A1
20020128638 Chauvet et al. Sep 2002 A1
20020133147 Marchitto et al. Sep 2002 A1
20020161326 Sussman et al. Oct 2002 A1
20020177846 Mulier et al. Nov 2002 A1
20020193789 Underwood et al. Dec 2002 A1
20030028189 Woloszko et al. Feb 2003 A1
20030040742 Underwood et al. Feb 2003 A1
20030097126 Woloszko et al. May 2003 A1
20030097129 Davison et al. May 2003 A1
20030099279 Venkatasubramanian et al. May 2003 A1
20030109869 Shadduck Jun 2003 A1
20030130655 Woloszko et al. Jul 2003 A1
20030130738 Hovda et al. Jul 2003 A1
20030144654 Hilal Jul 2003 A1
20030158545 Hovda et al. Aug 2003 A1
20030163178 Davison et al. Aug 2003 A1
20030181922 Alferness Sep 2003 A1
20030212394 Pearson et al. Nov 2003 A1
20030212395 Woloszko et al. Nov 2003 A1
20030225364 Kraft et al. Dec 2003 A1
20040024398 Hovda et al. Feb 2004 A1
20040024399 Sharps et al. Feb 2004 A1
20040031494 Danek et al. Feb 2004 A1
20040038868 Ingenito Feb 2004 A1
20040047855 Ingenito Mar 2004 A1
20040049180 Sharps et al. Mar 2004 A1
20040054366 Davison et al. Mar 2004 A1
20040055606 Hendricksen et al. Mar 2004 A1
20040068256 Rizoiu et al. Apr 2004 A1
20040068306 Shadduck Apr 2004 A1
20040087937 Eggers et al. May 2004 A1
20040116922 Hovda et al. Jun 2004 A1
20040193150 Sharkey et al. Sep 2004 A1
20040199226 Shadduck Oct 2004 A1
20040230190 Dahla et al. Nov 2004 A1
20040254532 Mehier Dec 2004 A1
20050004634 Ricart et al. Jan 2005 A1
20050010205 Hovda et al. Jan 2005 A1
20050070894 McClurken Mar 2005 A1
20050119650 Sanders et al. Jun 2005 A1
20050166925 Wilson et al. Aug 2005 A1
20050171582 Matlock Aug 2005 A1
20050187543 Underwood et al. Aug 2005 A1
20050215991 Altman et al. Sep 2005 A1
20050222485 Shaw et al. Oct 2005 A1
20050228423 Khashayar et al. Oct 2005 A1
20050228424 Khashayar et al. Oct 2005 A1
20050240171 Forrest Oct 2005 A1
20050267467 Paul et al. Dec 2005 A1
20050283143 Rizoiu Dec 2005 A1
20060004400 McGurk et al. Jan 2006 A1
20060047291 Barry Mar 2006 A1
20060085054 Zikorus et al. Apr 2006 A1
20060100619 McClurken et al. May 2006 A1
20060130830 Barry Jun 2006 A1
20060135955 Shadduck Jun 2006 A1
20060142783 Lewis et al. Jun 2006 A1
20060161233 Barry et al. Jul 2006 A1
20060200076 Gonzalez et al. Sep 2006 A1
20060206150 Demarais et al. Sep 2006 A1
20060224154 Shadduck et al. Oct 2006 A1
20060271111 Demarais et al. Nov 2006 A1
20070032785 Diederich et al. Feb 2007 A1
20070036417 Argiro et al. Feb 2007 A1
20070091087 Zuiderveld Apr 2007 A1
20070129720 Demarais et al. Jun 2007 A1
20070129760 Demarais et al. Jun 2007 A1
20070129761 Demarais et al. Jun 2007 A1
20070135875 Demarais et al. Jun 2007 A1
20070265687 Deem et al. Nov 2007 A1
20080033493 Deckman et al. Feb 2008 A1
20080097429 McClurken Apr 2008 A1
20080103566 Mehier May 2008 A1
20080110457 Barry et al. May 2008 A1
20080114297 Barry et al. May 2008 A1
20080125747 Prokop May 2008 A1
20080132826 Shadduck et al. Jun 2008 A1
20080213331 Gelfand et al. Sep 2008 A1
20080255642 Zarins et al. Oct 2008 A1
20090036948 Levin et al. Feb 2009 A1
20090054871 Sharkey et al. Feb 2009 A1
20090062873 Wu et al. Mar 2009 A1
20090076409 Wu et al. Mar 2009 A1
20090105702 Shadduck Apr 2009 A1
20090105703 Shadduck Apr 2009 A1
20090125009 Zikorus et al. May 2009 A1
20090149846 Hoey et al. Jun 2009 A1
20090216220 Hoey et al. Aug 2009 A1
20090306640 Glaze et al. Dec 2009 A1
20090312753 Shadduck Dec 2009 A1
20100076416 Hoey et al. Mar 2010 A1
20100094270 Sharma Apr 2010 A1
20100114083 Sharma May 2010 A1
20100137860 Demarais et al. Jun 2010 A1
20100137952 Demarais et al. Jun 2010 A1
20100160905 Shadduck Jun 2010 A1
20100168731 Wu et al. Jul 2010 A1
20100168739 Wu et al. Jul 2010 A1
20100174282 Demarais et al. Jul 2010 A1
20100179528 Shadduck et al. Jul 2010 A1
20100185189 Hoey Jul 2010 A1
20100191112 Demarais et al. Jul 2010 A1
20100204688 Hoey et al. Aug 2010 A1
20100222851 Deem et al. Sep 2010 A1
20100222854 Demarais et al. Sep 2010 A1
20100249773 Clark et al. Sep 2010 A1
20100262133 Hoey et al. Oct 2010 A1
20100268307 Demarais et al. Oct 2010 A1
20110060324 Wu et al. Mar 2011 A1
20110077628 Hoey et al. Mar 2011 A1
20110112400 Emery et al. May 2011 A1
20110118717 Shadduck May 2011 A1
20110160648 Hoey Jun 2011 A1
20110166499 Demarais et al. Jul 2011 A1
20110178570 Demarais Jul 2011 A1
20110200171 Beetel et al. Aug 2011 A1
20110202098 Demarais et al. Aug 2011 A1
20110208096 Demarais et al. Aug 2011 A1
20110257564 Demarais et al. Oct 2011 A1
20110264011 Wu et al. Oct 2011 A1
20110264075 Leung et al. Oct 2011 A1
20110264090 Shadduck et al. Oct 2011 A1
20120101413 Beetel et al. Apr 2012 A1
20120101538 Ballakur et al. Apr 2012 A1
20120116382 Ku et al. May 2012 A1
20120116383 Mauch et al. May 2012 A1
20120116486 Naga et al. May 2012 A1
20120130289 Demarais et al. May 2012 A1
20120130345 Levin et al. May 2012 A1
20120130359 Turovskiy May 2012 A1
20120130360 Buckley et al. May 2012 A1
20120130458 Ryba et al. May 2012 A1
20120136344 Buckley et al. May 2012 A1
20120136350 Goshgarian et al. May 2012 A1
20120136417 Buckley et al. May 2012 A1
20120136418 Buckley et al. May 2012 A1
20120143181 Demarais et al. Jun 2012 A1
20120143293 Mauch et al. Jun 2012 A1
20120150267 Buckley et al. Jun 2012 A1
20120158104 Huynh et al. Jun 2012 A1
20120172837 Demarais et al. Jul 2012 A1
20120197198 Demarais et al. Aug 2012 A1
20120197252 Deem et al. Aug 2012 A1
20120259271 Shadduck et al. Oct 2012 A1
20130079772 Shadduck Mar 2013 A1
20130116683 Shadduck et al. May 2013 A1
20130237978 Shadduck et al. Sep 2013 A1
20140018890 Hoey et al. Jan 2014 A1
20140025057 Hoey et al. Jan 2014 A1
20140031805 Shadduck Jan 2014 A1
Foreign Referenced Citations (10)
Number Date Country
WO 0011927 Mar 2000 WO
WO 0029055 May 2000 WO
WO 02069821 Sep 2002 WO
WO 03070302 Aug 2003 WO
WO 03086498 Oct 2003 WO
WO 2005025635 Mar 2005 WO
WO 2005102175 Nov 2005 WO
WO 2006003665 Jan 2006 WO
WO 2006055695 May 2006 WO
WO 2009009398 Jan 2009 WO
Non-Patent Literature Citations (60)
Entry
Coda, et al., “Effects of pulmonary reventilation on gas exchange after cryolytic disobstruction of endobronchial tumors,” Minerva Medical, vol. 72, pp. 1627-1631, Jun. 1981 (with English translation).
Fishman et al., “A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema,” N Engl J Med, vol. 348, No. 21, pp. 2059-2073, May 22, 2003.
Homasson, et al., “Bronchoscopic cryotherapy for airway strictures caused by tumors,” Chest, vol. 90, No. 2, pp. 159-164, Aug. 1986.
Li, K., “Efficient optimal net surface detection for image segmentation—from theory to practice” M.Sc. Thesis, The University of Iowa, 2003.
Marasso, et al., “Cryosurgery in bronchoscopic treatment of tracheobronchial stenosis,” Chest, vol. 103, No. 2, pp. 472-474, Feb. 1993.
Marasso, et al., “Radiofrequency resection of bronchial tumours in combination with cryotherapy: evaluation of a new technique,” Thorax, vol. 53, pp. 106-109, 1998.
Mathur et al., “Fiberoptic bronchoscopic cryotherapy in the management of tracheobronchial obstruction,” Chest, vol. 110, No. 3, pp. 718-723, Sep. 1996.
Morice at al, “Endobrinchial argon plasma coagulation for treatment of hemotysis and neoplastic airway obstruction,” Chest, vol. 119, No. 3, pp. 781-787, Mar. 2001.
Moulding et al., “Preliminary studies for achieving transcervical oviduct occlusion by hot water or low-pressure steam,” Advancesin Planned Parenthood, vol. 12, No. 2: pp. 79-85, 1977.
Quin, J., “Use of neodymium yttrium aluminum garnet laser in long-term palliation of airway obstruction,” Connecticut Medicine, vol. 59, No. 7, pp. 407-412, Jul. 1995.
Sutedja, et al., “Bronchoscopic treatment of lung tumors, ” Elsevier, Lung Cancer, 11, pp. 1-17, 1994.
Tschirren et al.: “Intrathoracic airway trees segmentation and airway morphology analysis from low-dose CT scans;” IEEE Trans. Med. Imaging, vol. 24, No. 12; pp. 1529-1539, Dec. 2005.
Tschirren, J., “Segmentation, anatomical labeling, branchpoint matching, and quantitative analysis of human airway trees in volumetric CT images,” Ph.D. Thesis, The University of Iowa, 231 pages, Aug. 2003.
Tschirren, J., “Segmentation, anatomical labeling, branchpoint matching, and quantitative analysis of human airway trees in volumetric CT images,” Slides from Ph.D. defense, University of Iowa, 130 pages, Aug. 2003.
Unger, M. at al. “Monolithic Microfabricated Valves and Pumps by Multilayer Soft Lithography,” Science, vol. 288, pp. 113-116, Apr. 7, 2000, accessed at http://web.mit.edu/thorsen/www/113.pdf.
Xia. Y. et al. “Soft Lithography,” Annu. Rev. Mater. Sci., vol. 28. pp. 153-184, 1998, accessed at http://www.bwfoundry.com/xia.pdf.
International Patent Application No. PCT/US2008/069094 in the name of TSUNAMI MEDTECH, LLC. filed Jul. 2, 2008, International Search Report and Written Opinion mailed Oct. 9, 2008.
Li, K., “Efficient optimal net surface detection for image segmentation—from theory to practice,” M.Sc. Thesis, The University of Iowa, 2003.
Morice et al. “Endobrinchial argon plasma coagulation for treatment of hemotysis and neoplastic airway obstruction,” Chest, vol. 119, No. 3, pp. 781-787, Mar. 2001.
Moulding et al., “Preliminary studies for achieving transcervical oviduct occlusion by hot water or low-pressure steam,” Advancesin Planned Parenthood, vol. 12, No. 2; pp. 79-85, 1977.
Quin, J , “Use of neodymium yttrium aluminum garnet laser in long-term palliation of airway obstruction,” Connecticut Medicine, vol. 59, No. 7, pp. 407-412, Jul. 1995.
Sutedja, et al., “Bronchoscopic treatment of lung tumors,” Elsevier, Lung Cancer, 11, pp. 1-17, 1994.
Topaz, et al., “Acute Results, Complications, and Effect of Lesion Characteristics on Outcome With the Solid-State,Pulsed Wave, Mid-Infrared Laser Angioplasty System”, Lasers in Surg. & Med., vol. 22, pp. 228-239, 1998.
Tschirren et al.; “Intrathoracic airway trees: segmentation and airway morphology analysis from low-dose CT scans:” IEEE Trans. Med. Imaging, vol. 24, No. 12; pp. 1529-1539, Dec. 2005.
U.S. Appl. No. 11/244,329, filed Oct. 5, 2005 in the name of Shadduck, Notice of Allowance mailed Dec. 2, 2010.
U.S. Appl. No. 11/244,329, filed Oct. 5, 2005 in the name of Shadduck, non-final Office Action mailed Jun. 19, 2009.
U.S. Appl. No. 11/244,329, filed Oct. 5, 2005, in the name of Shadduck, non-final Office Action mailed Mar. 22, 2010.
U.S. Appl. No. 09/181,906, filed Oct. 28, 1998, in the name of Shadduck, non-final Office Action mailed Mar. 15, 2000.
U.S. Appl. No. 09/181,906, filed Oct. 28, 1998, in the name of Shadduck, Notice of Allowance mailed Sep. 26, 2000.
U.S. Appl. No. 09/281,493, filed Mar. 30, 1999 in the name of Shadduck, entitled “Ionothermal system and technique for dermal treatments”.
U.S. Appl. No. 09/557,931, filed Apr. 22, 2000 in the name of Shadduck, entitled “Ionothermal delivery system and technique for medical procedures”.
U.S. Appl. No. 09/580,767, filed May 30, 2000 in the name of Shadduck, entitled “Microjoule electrical discharge catheter for thrombolysis in stroke patients”.
U.S. Appl. No. 09/782,649, filed Feb. 12, 2001, in the name of Shadduck, Notice of Allowance mailed Sep. 10, 2002.
U.S. Appl. No. 09/782,649, filed Feb. 12, 2001, in the name of Shadduck, Notice of Allowance mailed Sep. 9, 2002.
U.S. Appl. No. 10/017,582, filed Dec. 7, 2001 in the name of Shadduck, non-final Office Action mailed Dec. 10, 2002.
U.S. Appl. No. 10/017,582, filed Dec. 7, 2001 in the name of Shadduck, Notice of Allowance mailed Jul. 17, 2003.
U.S. Appl. No. 10/346,877, filed Jan. 18, 2003, in the name of Shadduck, Examiner's Amendment mailed Mar. 2, 2005.
U.S. Appl. No. 10/346,877, filed Jan. 18, 2003, in the name of Shadduck, Examiner's Amendment mailed Mar. 7, 2005.
U.S. Appl. No. 10/346,877, filed Jan. 18, 2003, in the name of Shadduck, non-final Office Action mailed Sep. 30, 2004.
U.S. Appl. No. 10/346,877, filed Jan. 18, 2003, in the name of Shadduck, Notice of Allowance mailed Mar. 7, 2005.
U.S. Appl. No. 10/681,625, filed Oct. 7, 2003, in the name of Shadduck, final Office Action mailed Jun. 3, 2008.
U.S. Appl. No. 10/681,625, filed Oct. 7, 2003, in the name of Shadduck, non-final Office Action mailed Aug. 15, 2007.
U.S. Appl. No. 10/681,625, filed Oct. 7, 2003, in the name of Shadduck, non-final Office Action mailed Mar. 13, 2009.
U.S. Appl. No. 10/681,625, filed Oct. 7, 2003, in the name of Shadduck, Notice of Allowance mailed Dec. 30, 2009.
U.S. Appl. No. 10/830,372, filed Apr. 22, 2004, in the name of Shadduck, Examiner Interview Summary mailed Feb. 12, 2008.
U.S. Appl. No. 10/830,372, filed Apr. 22, 2004, in the name of Shadduck, final Office Action mailed May 21, 2008.
U.S. Appl. No. 10/830,372, filed Apr. 22, 2004, in the name of Shadduck, non-final Office Action mailed Aug. 15, 2007.
U.S. Appl. No. 10/830,372, filed Apr. 22, 2004, in the name of Shadduck, Notice of Allowance mailed Apr. 7, 2009.
U.S. Appl. No. 11/158,930, filed Jun. 22, 2005, in the name of Shadduck, non-final Office Action mailed Dec. 24. 2009.
U.S. Appl. No. 11/158,930, filed Jun. 22, 2005, in the name of Shadduck, non-final Office Action mailed Jun. 24, 2009.
U.S. Appl. No. 11/158,930, filed Jun. 22, 2005, in the name of Shadduck, Notice of Allowance mailed Jul. 22, 2010.
U.S. Appl. No. 11/158,930, filed Jun. 22, 2005, in the name of Shadduck, Notice of Allowance mailed Oct. 7, 2010.
U.S. Appl. No. 11/329,381, filed Jan. 10, 2006, in the name of Shadduck, final Office Action mailed Jul. 14, 2010.
U.S. Appl. No. 11/329,381, filed Jan. 10, 2006, in the name of Shadduck, non-final Office Action mailed Dec. 9, 2009.
Unger, M. et al. “Monolithic Microfabricated Valves and Pumps by Multilayer Soft Lithography,” Science, vol. 288, pp. 113-116, Apr. 7, 2000, accessed at http://web.mit.edu/thorsen/www/113.pdf.
Xia, Y. et al. “Soft Lithography,” Annu. Rev. Mater. Sci., vol. 28, pp. 153-184, 1998, accessed at http://www.bwfoundry.com/xia.pdf.
European Patent Application No. 08781301.0 in the name of TSUNAMI MEDTECH, LLC. filed Jul. 2, 2008, Supplementary Search Report and Written Opinion mailed Feb. 28, 2011.
U.S. Appl. No. 11/244,329, filed Oct. 5. 2005, in the name of Shadduck, Notice of Allowance mailed Dec. 2, 2010.
U.S. Appl. No. 11/244,329, filed Oct. 5, 2005, in the name of Shadduck, Notice of Allowance mailed Apr. 5, 2011.
U.S. Appl. No. 11/329,381, filed Jan. 10, 2006, in the name of Shadduck, non-final Office Action mailed May 27, 2011.
Related Publications (1)
Number Date Country
20120065632 A1 Mar 2012 US
Provisional Applications (3)
Number Date Country
60615900 Oct 2004 US
60416622 Oct 2002 US
60254487 Dec 2000 US
Continuations (1)
Number Date Country
Parent 11244329 Oct 2005 US
Child 13229997 US
Continuation in Parts (6)
Number Date Country
Parent 10346877 Jan 2003 US
Child 11244329 US
Parent 09782649 Feb 2001 US
Child 10346877 US
Parent 09181906 Oct 1998 US
Child 09782649 US
Parent 09049711 Mar 1998 US
Child 09181906 US
Parent 10681625 Oct 2003 US
Child 09049711 US
Parent 10017582 Dec 2001 US
Child 10681625 US